Compare Amgen, Inc. (AMGN) vs Firy Inc. (FIRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Firy Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Firy Inc. trades at $8.54 (market cap $133.29M). The key difference: Amgen, Inc. is far larger — about 1471.4× Firy Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| AMGN | FIRY | |
|---|---|---|
Market Cap | $196.12B | $133.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $12.45 |
52-Week Low | $271.18 | $2.28 |
Enterprise Value | $241.41B | $76.96M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FIRY (formerly Skillz) trades at $8.54, down 3.06% today, amid a recent rebrand and mixed quarterly results. The stock shows a bullish technical signal with support near $8 and resistance at $9, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; while technicals suggest near-term strength, fundamental challenges from sustained unprofitability and high cash burn pose significant risks. Analyst sentiment is mixed with 60% hold ratings, reflecting uncertainty over the company's turnaround amid competitive pressures in mobile gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
